- Home
- RNG vs VCRE Comparison
RNG vs VCRE Comparison
Compare RNG & VCRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RNG | VCRE |
|---|---|---|
| Founded | 1999 | N/A |
| Country | United States | Sweden |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.3B |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | RNG | VCRE |
|---|---|---|
| Price | $48.67 | $11.38 |
| Analyst Decision | Hold | |
| Analyst Count | 14 | 0 |
| Target Price | ★ $33.58 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 3.3K |
| Earning Date | 05-07-2026 | N/A |
| Dividend Yield | ★ 0.75% | N/A |
| EPS Growth | ★ 176.19 | N/A |
| EPS | ★ 0.80 | N/A |
| Revenue | ★ $2,515,142,000.00 | N/A |
| Revenue This Year | $5.56 | N/A |
| Revenue Next Year | $4.56 | N/A |
| P/E Ratio | $110.34 | ★ N/A |
| Revenue Growth | ★ 4.78 | N/A |
| 52 Week Low | $23.59 | $11.00 |
| 52 Week High | $49.85 | $12.85 |
Technical Indicators
Market Signals| Indicator | RNG | VCRE |
|---|---|---|
| Relative Strength Index (RSI) | 69.47 | 17.44 |
| Support Level | $37.92 | N/A |
| Resistance Level | N/A | $12.85 |
| Average True Range (ATR) | 2.62 | 0.55 |
| MACD | 0.47 | -0.11 |
| Stochastic Oscillator | 94.71 | 20.54 |
Price Performance
Historical ComparisonAbout RNG RingCentral Inc.
RingCentral is a unified communications as a service, or UCaaS, provider. Its software helps users communicate and collaborate via voice, video, and messaging across all device types and all from one platform. RingCentral helps customers modernize and move from legacy on-premises systems to modern, cloud-based systems. Beyond its core RingCentral MVP solution, RingCentral also offers a cloud-based contact center solution, a stand-alone video meetings solution, and webinars.
About VCRE Vicore Pharma Holding AB American Depositary Shares
Vicore Pharma Holding AB is a clinical-stage biopharmaceutical company developing a new class of disease-modifying therapies for respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). Its main program, buloxibutid, is an oral angiotensin II type 2 receptor agonist that has received Orphan Drug and Fast Track designation from the U.S. Food and Drug Administration and is currently being evaluated in the 52-week Phase 2b ASPIRE trial in IPF. Currently, Vicore is operating mainly in Sweden.